Skip to main content

Advertisement

Table 4 Log-rank analysis of prognostic factors in cervical squamous cell carcinoma patients

From: Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma

Factor PFS OS
3-year (%) χ 2 P-value 3-year (%) χ 2 P-value
Age
(year)
≤54 84.91 3.963 0.047 88.66 2.392 0.122
> 54 64.52 67.74
Family history of cancer No 71.70 1.884 0.170 75.47 1.618 0.203
Yes 100.00 100.00
History of miscarriage No 66.67 2.299 0.129 74.07 0.945 0.331
Yes 80.33 80.33
Tumor size
(cm)
≤5 73.68 0.027 0.870 78.95 0.085 0.771
> 5 74.36 74.36
Tumor type Cauliflower 76.74 0.214 0.644 76.74 0.033 0.857
Nodular 72.00 76.00
Hollow 57.14 71.43
Others 100.00 100.00
Histologic grade Well 50.00 0.239 0.625 50.00 0.066 0.797
Moderate 75.31 80.25
Poor 66.67 66.67
Papillary 83.33 83.33
FIGO stage IIB 82.46 1.271 0.260 82.46 1.166 0.280
IIIA-IIIB 72.41 65.52
SCC-Ag Normal 90.00 1.854 0.173 90.00 1.367 0.242
Anormal 70.53 74.74
CEA Normal 80.56 1.951 0.163 86.00 3.238 0.072
Anormal 62.79 62.79
TSGF Normal 72.84 0.191 0.662 77.78 0.003 0.960
Anormal 76.47 76.47
Pelvic lymph nodes No 79.59 1.698 0.193 79.59 0.571 0.450
Yes 69.70 75.76
HPV E1 Positive 85.29 5.307 0.021 91.18 8.078 0.004
Negative 57.45 57.45
Treatment Radiotherapy + chemotherapy 78.13 1.073 0.300 81.25 0.265 0.607
Radiotherapy 68.63 72.55
  1. FIGO International Federation of Gynecology and Obstetrics, SCC-Ag Squamous cell carcinoma antigen, CEA carcinoembryonic antigen, TSGF Tumor specific growth factor, HPV Human papillomavirus